Sort
48,018 grants matching “immunotherapy”
Development of a protein drug for pancreatic cancer treatment
$999,780Zhi-Ren Liu · Proda Biotech, Llc · R42 · FY2019 · CA
Reprogramming the Tumor-Immune Interface in Oral Cancer
$999,772John B Sunwoo · Stanford University · R35 · FY2022 · DE
Herpes Simplex Immunotherapeutic Vaccine
$999,688Sean M. Sullivan · Vical, Inc. · R42 · FY2008 · AI
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
$999,658Samirkumar Patel · Moonlight Therapeutics, Inc. · U44 · FY2025 · AI
A Single-cell Platform for Analyzing the Peripheral Immune Response in Alzheimerâs and Alzheimerâs Related Diseases
$999,615Timothy S McConnell · Isoplexis, Inc. · R44 · FY2020 · AG
A Prognostic Blood Test to Monitor Pancreatic Cancer Treatment by MiRNA Profiling
$999,597Ravi Saraf · Vajra Instruments, Inc. · R44 · FY2019 · CA
A Prognostic Blood Test to Monitor Pancreatic Cancer Treatment by MiRNA Profiling
$999,597Ravi Saraf · Vajra Instruments, Inc. · R44 · FY2018 · CA
Induction of an Antitumor Immune Response in Patients with Melanoma
$999,555Patrick Hwu · University Of Tx Md Anderson Can Ctr · P50 · FY2011 · CA
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$999,501Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2018 · CA
A Novel PET Probe for Use in Cancer Diagnostics
$999,412Melissa Moore · Sofie Biosciences, Inc. · R44 · FY2018 · CA
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$999,369Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2022 · CA
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2021 · CA
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
$999,300Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2022 · AI
Humanized monoclonal antibodies to treat mucormycosis
$999,218Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2025 · AI
Development of GIFT4: a B cell focused immunotherapy for cancer
$999,088Paul Guyre · Celdara Medical, Llc · R44 · FY2017 · CA
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
$999,063Jana Portnow · Beckman Research Institute/City Of Hope · U19 · FY2021 · CA
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
$999,032Richard A Cone · Mucommune, Llc · R44 · FY2020 · AI
Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer
$998,971Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2025 · CA
Liquid Immunotherapeutic Fiducial Eluter (LIFE) Gel for Cervical Cancer
$998,781Adam Shilling · Nanocan Therapeutics Corporation · R42 · FY2025 · CA
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy
$998,324Irving Lerner Weissman · Stanford University · R35 · FY2022 · CA
Administrative Core for SWOG SDMC
$998,260Michael Leo Leblanc · Fred Hutchinson Cancer Research Center · U10 · FY2019 · CA
Induction of an Antitumor Immune Response in Patients with Melanoma
$998,246Patrick Hwu · University Of Tx Md Anderson Can Ctr · P50 · FY2014 · CA
Leadership, Planning and Evaluation
$997,983Alan Ashworth · University Of California, San Francisco · P30 · FY2024 · CA
Leadership, Planning and Evaluation
$997,892Alan Ashworth · University Of California, San Francisco · P30 · FY2023 · CA